Presbia PLC (NASDAQ:LENS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday, July 25th.
According to Zacks, “Presbia PLC offers ophthalmic device. It is focused on the development and marketing of an optical lens implant for the treatment of presbyopia. The company’s product consists of Presbia Flexivue Microlens(TM). Presbia PLC is based in Irvine, California. “
Several other research analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Presbia PLC in a research report on Tuesday, May 23rd. Rodman & Renshaw lowered their target price on Presbia PLC from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Monday, May 22nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. Presbia PLC has an average rating of “Hold” and an average price target of $12.00.
Presbia PLC (NASDAQ:LENS) traded down 1.48% during trading on Tuesday, hitting $2.66. The stock had a trading volume of 210 shares. The firm’s market cap is $45.10 million. Presbia PLC has a 52 week low of $1.86 and a 52 week high of $5.50. The company’s 50-day moving average is $2.41 and its 200 day moving average is $2.87.
An institutional investor recently raised its position in Presbia PLC stock. FMR LLC increased its stake in Presbia PLC (NASDAQ:LENS) by 26.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,554,903 shares of the medical instruments supplier’s stock after buying an additional 541,764 shares during the period. FMR LLC owned 19.15% of Presbia PLC worth $8,022,000 at the end of the most recent quarter. 19.58% of the stock is currently owned by institutional investors.
About Presbia PLC
Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.
Get a free copy of the Zacks research report on Presbia PLC (LENS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Presbia PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related companies with MarketBeat.com's FREE daily email newsletter.
